Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19-Reference-Cited by-同舟云学术

Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19

Published:2023-04 Issue:2 Volume:45 Page:191-199
ISSN:0163-4356
Container-title:Therapeutic Drug Monitoring
language:en
Short-container-title:

Author:

Lemaitre Florian,Budde Klemens,Van Gelder Teun,Bergan Stein,Lawson Roland,Noceti Ofelia,Venkataramanan Raman,Elens Laure,Moes Dirk Jan A. R.,Hesselink Dennis A.,Pawinski Tomasz,Johnson-Davis Kamisha L.,De Winter Brenda C. M.,Pattanaik Smita,Brunet Mercè,Masuda Satohiro,Langman Loralie J.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Pharmacology (medical),Pharmacology

Reference51 articles.

1. Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19;Hammond;N Engl J Med.,2022

2. COVID-19: outpatient evaluation and management of acute illness in adults;Cohen;UpToDate,2022

3. Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: guidelines from the French Society of Pharmacology and Therapeutics (SFPT);Lemaitre;Therapies,2022

4. Induction effects of ritonavir: implications for drug interactions;Foisy;Ann Pharmacother.,2008

5. Pharmacokinetic drug evaluation of ritonavir (versus cobicistat) as adjunctive therapy in the treatment of HIV;Cattaneo;Expert Opin Drug Metab Toxicol.,2019

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect of rifampicin administration on CYP induction in a dermatomyositis patient with vasospastic angina attributable to nilmatrelvir/ritonavir-induced blood tacrolimus elevation: A case report;Journal of Infection and Chemotherapy;2024-09

2. Supply of nirmatrelvir/ritonavir and molnupiravir for patients with COVID-19 in the first eight months since listing on the Australian Pharmaceutical Benefits Scheme: A retrospective observational study;Infectious Diseases Now;2024-09

3. A Perspective on Evaluating Life Stage Differences in Drug Dosages for Drug Labeling and Instructions;The AAPS Journal;2024-08-20

4. Population pharmacokinetics of nirmatrelvir in Chinese patients with COVID-19: Therapeutic drug monitoring and dosing regimen selection in clinical practice;International Journal of Antimicrobial Agents;2024-08

5. Influence of ensitrelvir or nirmatrelvir/ritonavir on tacrolimus clearance in kidney transplant recipients: a single-center case series;Journal of Pharmaceutical Health Care and Sciences;2024-07-10